Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

tippy_09137 617 posts  |  Last Activity: May 26, 2015 7:20 PM Member since: Dec 9, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 4 Sullivan, eugene jeffrey May 26, 2015
    4 Schaeffer, orlov s nicole May 26, 2015
    4 Pellizzari, christine a May 26, 2015
    4 Lewis, william May 26, 2015
    4 Drechsler, andrew t May 26, 2015

  • Reply to

    OT: ISR stock

    by tippy_09137 May 20, 2015 10:29 PM
    tippy_09137 tippy_09137 May 20, 2015 10:31 PM Flag

    Why doesn't INSM release news on the results from the poster board? Better than expected!!

  • tippy_09137 by tippy_09137 May 20, 2015 10:29 PM Flag

    IsoRay reports that the survival rate at 5 years was 100% for Cesium-131 lung cancer treatment group, which included many high risk patients, and Cesium-131 added no noticeable side effects (ISR) :

    The study noted that the survival rate at 5 years was exceptional for the Cesium-131 group, which included many high risk patients, and Cesium-131 added no noticeable side effects. Treatment with Cesium-131 was performed at the time of the surgery as a single treatment, in contrast to another treatment option, external radiation, which requires numerous hospital visit.

  • tippy_09137 by tippy_09137 Mar 8, 2015 8:24 AM Flag

    Anyone following this stock? Looks like has great growth potential.

    "We are extremely pleased with the growth of Forfivo XL(R) throughout 2014 and we believe that this growth will continue, especially as Edgemont increased its salesforce threefold in mid-December, 2014" stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "The marketing and sales efforts that our partner, Edgemont Pharmaceuticals, has invested in the commercialization of Forfivo XL(R) have ensured that a more convenient and safe alternative for patients requiring high-dose anti-depressant therapy is widely available in the US. Forfivo XL(R) generated in excess of $1.1 million (unaudited) of revenue for IntelGenx in 2014 and we anticipate significantly higher revenue from the product in 2015."

  • Reply to

    Heads Up......

    by insmhistorian Jul 26, 2014 11:06 PM
    tippy_09137 tippy_09137 Jul 27, 2014 7:55 AM Flag

    What do you think that indicates?

  • Reply to

    OT GOD'S NOT DEAD.....

    by insmhistorian Apr 25, 2014 4:13 PM
    tippy_09137 tippy_09137 Apr 25, 2014 7:18 PM Flag

    Amen....God is good all the time. Heaven is for Real is a also a great movie.

  • April 25 (Reuters) - Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease - a progressive neurodegenerative disorder - failed the main goal in a mid-stage trial.

    The study tested the efficacy of the drug, tirasemtiv - one of the company's lead compounds - against a placebo in 711 patients with amyotrophic lateral sclerosis (ALS).

    The San Francisco-based company's stock was halted before the bell on Friday.

  • tippy_09137 by tippy_09137 Apr 17, 2014 6:03 PM Flag

    Insmed Incorporated
    9 Deer Park Drive, Suite C
    Monmouth Junction, NJ 08852-1923
    (732) 997-4600

    ANNUAL MEETING OF SHAREHOLDERS

    April 17, 2014

    To the Shareholders:

    We cordially invite you to attend the 2014 Annual Meeting of Shareholders to be held at the Bridgewater Marriott, 700 Commons Way, Bridgewater, New Jersey 08807, on May 29, 2014, at 9:00 a.m. local time (the "Annual Meeting"). A formal notice of the meeting, together with a proxy statement and proxy form, is enclosed with this letter. The notice points out that you will be asked to:

    (i)
    elect two Class II directors, Donald Hayden, Jr. and David W.J. McGirr, to serve until the 2017 Annual Meeting of Shareholders;

    (ii)
    conduct an advisory vote on the compensation of our named executive officers;

    (iii)
    ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014; and

    (iv)
    transact such other business as may properly come before the meeting.

    Please read the notice and proxy statement carefully, and vote by telephone, electronically through the Internet, by completing, signing and mailing the enclosed proxy card promptly, or in person at the Annual Meeting.

  • Interesting.....

  • Bid: 19.15 x 300
    Ask: 132.06 x 8000

  • tippy_09137 by tippy_09137 Jan 16, 2014 4:18 PM Flag

    Jan 16, 2014

    Form 8-K / Current Report

  • Reply to

    New From 4's

    by tippy_09137 Jan 14, 2014 4:29 PM
    tippy_09137 tippy_09137 Jan 14, 2014 4:32 PM Flag

    Jan 14, 2014

    Form 4 / Drechsler, Andrew T
    HTML PDF

    Form 4 / Gupta, Renu
    HTML PDF

    Form 4 / Lewis, William
    HTML PDF

    Form 4 / Pellizzari, Christine A
    HTML PDF

    Form 4 / Pauls, Matthew
    HTML PDF

  • tippy_09137 by tippy_09137 Jan 14, 2014 4:29 PM Flag

    Jan 14, 2014

    Form 4 / Engelsen, Steinar J
    HTML PDF

    Form 4 / Hayden, Donald J Jr
    HTML PDF

    Form 4 / Altomari, Alfred
    HTML PDF

    Form 4 / Sharoky, Melvin Md
    HTML PDF

    Form 4 / Mcgirr, David W J
    HTML PDF

    Form 4 / Whitcomb, Randall W
    HTML PDF

    View all SEC Filings

  • tippy_09137 tippy_09137 Sep 2, 2013 5:27 PM Flag

    Do you have a link......thanks.

  • Stock Option-Right to Buy $11.14 7/30/2013 A 150000 7/29/2014 (1) 7/30/2023 (1) Common Stock 150000 $0 150000 D

  • Reply to

    Mr Lewis Form 4

    by tippy_09137 Jul 1, 2013 9:13 PM
    tippy_09137 tippy_09137 Jul 1, 2013 9:17 PM Flag

    Common Stock 7/1/2013 P (1) 4000 A $9.28 (2) 38154
    Common Stock 7/1/2013 P (1) 3585 A $10.44 (3) 41739

  • tippy_09137 by tippy_09137 Jul 1, 2013 9:13 PM Flag

    Acquired 7500 shares......

  • tippy_09137 tippy_09137 Jun 25, 2013 8:30 PM Flag

    By combining these two therapies, researchers found that in addition to increased body and muscle weight, mice showed enhanced locomotory capacities and remarkable improvement in muscle pathology. The most impressive outcome was the significant resolution of inflammation and fibrosis, not seen with single mode therapies. The research team concluded that the use of this combination therapy is an effective treatment for MDC1A, highlighting a compelling argument that a combinatorial approach has a synergistic benefit and could have the potential of treating patients with congenital muscular dystrophy.

  • The study was led by Mahasweta Girgenrath, PhD, assistant professor and director of the Muscle Disorders and Regenerative Biology Laboratory at BU Sargent College's Department of Health Sciences. Boston University (BU) researchers and postdoctoral fellows Jenny Yamauchi, Ajay Kumar, Lina Duarte, and Thomas Mehuron were collaborators on this study.

    Muscular Dystrophy type 1A (MDC1A) is the second most common form of congenital muscular dystrophy. Patients with this disease have poor muscle tone at birth, extremely compromised neuromuscular function, and are rarely able to walk independently. Most patients with MDC1A succumb to a premature death due to either respiratory complications or failure to thrive. Although significant strides have been made towards understanding the molecular and biochemical mechanisms underlying MDC1A, there remains no effective therapy in place to combat this lethal disease.

    The research team, led by Girgenrath, hypothesized that the complex pathology seen in MDC1A may be the result of dysregulation of multiple cellular functions and processes, meaning that strategies which simultaneously target several of those mechanisms might lead to a reduction of symptoms.

    "Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy." said Professor Girgenrath, the study's corresponding author. "While most MD treatments are single-target therapies, we're delving into combinations of different therapies to target multiple pathways."

    The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed)

  • Reply to

    Insmed: Canaccord Genuity raises price target

    by tippy_09137 May 22, 2013 6:35 AM
    tippy_09137 tippy_09137 May 22, 2013 7:52 AM Flag

    All good.....nice to see our INSM finally getting some respect.

INSM
12.79-0.02(-0.16%)Feb 11 3:59 PMEST